George Clinical’s scientific expertise is derived from leading researchers with a track record in developing new strategies for the treatment and prevention of kidney disease across diverse populations. George Clinical leverages this expertise and prominence in the renal field to design effective studies and accelerate recruitment. George Clinical aims to make an impact with all its trials and as such generates strong clinical evidence for new therapies and devices.
George Clinical’s scientific expertise is derived from researchers with a leading track record of developing new strategies for the prevention and treatment of kidney diseases, for example by targeting their key risk factors such as blood pressure and diabetes. They also focus on improving outcomes for people with established kidney disease, such as those requiring dialysis. George Clinical leverages this in-depth knowledge and prominence in the renal field to design effective studies and accelerate recruitment.
George Clinical aims to make an impact with all its trials and as such generates strong clinical evidence for new therapies and devices.
Some of George Clinical’s success in renal studies include:
Our clinical trial services in renal health include:
Our renal site network is one of the strongest in the world, and especially in Asia.
Vlado Perkovic is Executive Director of The George Institute, Australia, Professor of Medicine at UNSW Sydney, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He leads several major international clinical trials, serves on the steering committees of several others, and has led the development of George Clinical, the global clinical trials arm of The George Institute. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management.
Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is a member of the National Health and Medical Research Council Principal Committee on Research Translation; Chair of the International Society of Nephrology Action for Clinical Trials (ISN-ACT) group; and Fellow of the Royal Australasian College of Physicians and of the American Society of Nephrology.
A/Prof Meg Jardine is a clinician researcher developing a program of research exploring the cardiovascular and other complications of chronic kidney disease and diabetes.
Dr. Jardine has worked as a Nephrologist in both the public and private sectors, where she directly manages chronic kidney disease and diabetes and their consequences for patients.
She is currently Deputy Director of the Renal & Metabolic Division at the George Institute for Global Health; Associate Professor at the Faculty of Medicine, UNSW Sydney; and holds an NHMRC Career Development Fellowship. She has presented her work in late breaking and prize sessions of the World Congress of Nephrology and the Australasian Nephrology conference and has published in high impact journals. Dr. Jardine is collaborating on the development and delivery of other national and international trials investigating methods to mitigate the excess burden of cardiovascular disease and is Chair of the Australasian Kidney Trials Network Haemodialysis Working Group.
Martin holds positions as Associate Professor, Faculty of Medicine, UNSW Sydney, Associate Professor of Medicine at Concord Hospital Clinical School (part of the Sydney Medical School), Director of the Renal and Metabolic Division in the George Institute and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy.
Martin’s research interests include large scale clinical trials to explore ways to improve the outcomes of patients with kidney disease (esp. in the setting of acute kidney injury), extending the follow up of such clinical trials to understand the long-term effects of treatments, measurement of health systems and the means of applying research evidence into practice.
Dr. Wong is Renal Physician at the Royal North Shore hospital, Sydney, Australia. He is also a senior research fellow at the George Institute of Global Health and holds a Senior Lecturer position, Faculty of Medicine, UNSW Sydney. His PhD entitled “Novel therapeutic options in models of nephropathy” was awarded in 2011.
His main area of research is in understanding the pathomechanisms of kidney tubulointerstitial fibrosis and biomarkers in predicting progression of chronic kidney disease particularly in diabetic kidney disease.
Dr. Wong has worked on kidney injury molecule-1, transforming growth factor-β1, bone morphogenetic protein-7, Farnesoid X receptor and novel anti-fibrotic and anti-inflammatory agents in extracellular matrix deposition in human proximal tubular cells and in vivo model of fibrosis.
His is also passionate in translation medicine and is involved in the post hoc analyses of the IDEAL study and currently involved in multicentre international trials at the George Institute including TESTING and SONAR study.
Professor Vivekanand Jha is the Executive Director, The George Institute for Global Health, India, and James Martin Fellow at The George Institute for Global Health at the University of Oxford.
Prior to joining The George Institute, he was Professor of Nephrology and Head, Department of Translational Regenerative Medicine and Officer-In-Charge, Medical Education and Research Cell at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. Vivek serves on the international advisory boards of several organisations, including membership of the WHO Expert Advisory Panel on Human Cell, Tissue and Organ Transplantation, and the executive committee of the International Society of Nephrology.
He is a councillor of the International Society of Nephrology, a member of the education committees for the International Transplantation Society and International Society of Peritoneal Dialysis. He is a physician with a specialization in the area of kidney diseases and he focuses on emerging public health threats globally and in India. He is particularly interested in using multi-disciplinary approaches and innovation to address the major challenge posed to humanity by non-communicable diseases.
Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with renal impairment. Based on this work, he was awarded a young investigator grant and, subsequently in 2015, a consolidator investigator grant from the Dutch organization of scientific research.
Since 2010, Professor Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimizing treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals, he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.